Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Review

Published on 04 Jul 2023

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

in Pharmacology of Anti-Cancer Drugs

Ram Kumar Sahu
Sakina Ruhi
Ashok Kumar Jeppu
Husni Ahmed Al-Goshae
Ayesha Syed
Sanjay Nagdev
Retno Widyowati
Wiwied Ekasari
Jiyauddin Khan
Bedanta Bhattacharjee

Frontiers in Oncology

doi 10.3389/fonc.2023.1204722

11,159 views
17 citations

Case Report

Published on 03 Jul 2023

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

in Pharmacology of Anti-Cancer Drugs

Ge Xiong
Richard Benjamin Young
Helen Chow
Emanual Maverakis
Ricardo A. Maselli
David Paul Richman
Tianhong Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1199195

4,422 views
3 citations

Case Report

Published on 30 Jun 2023

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment

in Pharmacology of Anti-Cancer Drugs

Gangyi Dai
Lang He
Qin Yan
Yamao Li
Yuandong Huang
Bin Li
Guoping Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1167516

2,844 views
7 citations

Editorial

Published on 26 Jun 2023

Editorial: Novel targeted drugs for indolent lymphoid malignancies

in Pharmacology of Anti-Cancer Drugs

Tadeusz Robak
Bartosz Puła
Iwona Hus

Frontiers in Oncology

doi 10.3389/fonc.2023.1224528

1,745 views

Editorial

Published on 20 Jun 2023

Editorial: Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer, Volume II

in Pharmacology of Anti-Cancer Drugs

Weilong Zhong
Tao Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1218855

2,046 views
3 citations

Original Research

Published on 20 Jun 2023

Adjuvant composite cold atmospheric plasma therapy increases antitumoral effect of doxorubicin hydrochloride

in Pharmacology of Anti-Cancer Drugs

Volha Kniazeva
Dzmitry Tzerkovsky
Ömür Baysal
Alexander Kornev
Evgeny Roslyakov
Serhei Kostevitch

Frontiers in Oncology

doi 10.3389/fonc.2023.1171042

3,085 views
6 citations

Editorial

Published on 19 Jun 2023

Editorial: RNA recognition landscapes and anticancer drug targeting

in Pharmacology of Anti-Cancer Drugs

Erica Salvati
Anna Lewinska
Erik Dassi
Maciej Wnuk
Vito G. D’Agostino

Frontiers in Oncology

doi 10.3389/fonc.2023.1222883

1,164 views

Review

Published on 19 Jun 2023

Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma

in Pharmacology of Anti-Cancer Drugs

Yubo Xiang
Yingxin Yang
Jia Liu
Xu Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1219211

6,060 views
9 citations

Review

Published on 16 Jun 2023

Anticancer properties of sulforaphane: current insights at the molecular level

in Pharmacology of Anti-Cancer Drugs

Muhammad Asif Ali
Noohela Khan
Nabeeha Kaleem
Waqas Ahmad
Salem Hussain Alharethi
Bandar Alharbi
Hassan H. Alhassan
Maher M. Al-Enazi
Ahmad Faizal Abdull Razis
Babagana Modu

Frontiers in Oncology

doi 10.3389/fonc.2023.1168321

27,692 views
35 citations

Original Research

Published on 15 Jun 2023

Evaluating the iron chelator function of sirtinol in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Michael S. Petronek
Khaliunaa Bayanbold
Koffi Amegble
Ann M. Tomanek-Chalkley
Bryan G. Allen
Douglas R. Spitz
Charvann K. Bailey

Frontiers in Oncology

doi 10.3389/fonc.2023.1185715

2,499 views
7 citations

Correction

Published on 02 Jun 2023

Corrigendum: Antiproliferative effects of the natural oxadiazine Nocuolin A are associated with impairment of mitochondrial oxidative phosphorylation

in Pharmacology of Anti-Cancer Drugs

Maria Lígia Sousa
Marco Preto
Vítor Vasconcelos
Stig Linder
Ralph Urbatzka

Frontiers in Oncology

doi 10.3389/fonc.2023.1228436

944 views

Case Report

Published on 31 May 2023

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule

in Pharmacology of Anti-Cancer Drugs

Maria Susanna Grimaudo
Alice Laffi
Nicolò Gennaro
Roberta Fazio
Federico D’Orazio
Laura Samà
Licia Vanessa Siracusano
Federico Sicoli
Salvatore Lorenzo Renne
Armando Santoro

Frontiers in Oncology

doi 10.3389/fonc.2023.1190123

2,145 views
1 citation

Original Research

Published on 29 May 2023

Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study

in Pharmacology of Anti-Cancer Drugs

Lei Wang
Zhong Su
Chunying Xie
Ruijun Li
Wei Pan
Lu Xu
Fei Chen
Gang Cheng

Frontiers in Oncology

doi 10.3389/fonc.2023.1165437

2,285 views
3 citations

Original Research

Published on 26 May 2023

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma

in Pharmacology of Anti-Cancer Drugs

Matthias A. Fante
Dennis C. Harrer
Barbara Zartner
Florian Lüke
Stephanie Mayer
Karin Menhart
Albrecht Reichle
Wolfgang Herr
Martin Vogelhuber
Daniel Heudobler

Frontiers in Oncology

doi 10.3389/fonc.2023.1177330

2,711 views
3 citations

Original Research

Published on 25 May 2023

Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins

in Pharmacology of Anti-Cancer Drugs

Sophia Steinlein
Frank Essmann
Amanda Franceschini Ghilardi
Heike Horn
Julia Schüler
Angelika Hausser
Lijun Sun
German Ott
Claudia Kalla

Frontiers in Oncology

doi 10.3389/fonc.2023.1190988

2,727 views
2 citations

Opinion

Published on 18 May 2023

Development of ZD2767P–carboxypeptidase G2–ultrasound therapy against cisplatin-resistant cancer

in Pharmacology of Anti-Cancer Drugs

Tinghe Yu
Xinya Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1151613

2,864 views
5 citations